RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
The National Immunisation Programme in the Netherlands: Developments in 2013 Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).
Nanotechnology in the fight against cancer Nanotechnology offers improved options for the diagnosis and treatment of cancer.
Cervical cancer screening in the Netherlands January 19 - 25 European Cervical Cancer Prevention Week.
Is screening for sexually transmitted infections as part of HIV care cost-effective in the Netherlands? Routine screening for anorectal chlamydia among HIV-positive men who have sex with men (MSM) could avert further spread of chlamydia and HIV in the total MSM population.
Regional differences in testing rates underestimate incidence of LGV epidemic Until 2003, Lymphogranuloma venereum (LGV), an aggressive form of chlamydia, was considered to be a rare tropical disease, endemic to Africa, Asia and the Caribbean.
Fewer municipalities with low vaccination coverage In the Netherlands, there are 80 municipalities with a low vaccination coverage for one or more vaccinations. This is a decrease compared to last year when there were still 90 municipalities.
More people visiting STI clinics in 2012 with chlamydia and gonorrhea infections In 2012, the number of new consultations at Sexually Transmitted Infections (STI) clinics in the Netherlands increased by 7% over the previous year.
Regulation of nanomaterials needs more than definition alone In a new publication, RIVM indicates scientific challenges in the use of the EU definition for nanomaterial in legislation.